ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1715925
Sentiment: neutral
Topics: 6-K, regulatory-filing, press-release
TL;DR
IPA files 6-K with press release on Dec 23rd. Stay tuned for details.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on December 23, 2024, to report information for the month of December 2024. The filing includes a press release dated December 23, 2024, as Exhibit 99.1. The company is incorporated in A1 and its fiscal year ends on April 30.
Why It Matters
This filing provides an update on the company's activities and disclosures for the period, which is important for investors to stay informed about the company's ongoing operations and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- December 23, 2024 (date) — Press Release Date
- Kristin Taylor (person) — Signatory for the company
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is a report of foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of December 2024.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release dated December 23, 2024, is included in this filing.
What is the principal executive office address of ImmunoPrecise Antibodies Ltd.?
The principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Does ImmunoPrecise Antibodies Ltd. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under Form 20-F.
Who signed this report on behalf of ImmunoPrecise Antibodies Ltd.?
The report was signed by Kristin Taylor, on behalf of ImmunoPrecise Antibodies Ltd.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-12-23 09:03:44
Filing Documents
- press_release_dec_23_202.htm (6-K) — 22KB
- ipa-ex99_1.htm (EX-99.1) — 14KB
- 0000950170-24-139301.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: December 23, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer